His primary areas of study are Immunology, Immune system, Antibody, Antigen and Virology. Immunology is often connected to Cell biology in his work. His Immune system study deals with Adjuvant intersecting with Circumsporozoite protein, Immune checkpoint, MART-1 Antigen and CCL18.
Tibor Keler mostly deals with Monoclonal antibody in his studies of Antibody. The Cross-presentation research Tibor Keler does as part of his general Antigen study is frequently linked to other disciplines of science, such as Mannose receptor, therefore creating a link between diverse domains of science. His work in Virology addresses subjects such as Dendritic cell, which are connected to disciplines such as Immunoglobulin G and Viral vector.
Tibor Keler focuses on Immunology, Antibody, Cancer research, Immune system and Monoclonal antibody. His Antibody research integrates issues from T cell, CD70, Receptor and Virology. His studies deal with areas such as Agonist, Cytotoxic T cell, Blockade and Lymphoma as well as Cancer research.
As part of his studies on Immune system, Tibor Keler frequently links adjacent subjects like Adjuvant. His Monoclonal antibody study incorporates themes from Molecular biology, Genetically modified mouse, Transgene and Fc receptor. In general Antigen, his work in Cross-presentation is often linked to Mannose receptor linking many areas of study.
Tibor Keler spends much of his time researching Cancer research, Immune system, T cell, Antibody and CD8. The various areas that Tibor Keler examines in his Cancer research study include CD40, Agonist, Receptor, Blockade and Monoclonal antibody. His Immune system research focuses on subjects like Cytokine, which are linked to Pharmacology.
The concepts of his Antibody study are interwoven with issues in CD70 and Pharmacodynamics. His Immunotherapy study is concerned with the field of Immunology as a whole. His work carried out in the field of Immunology brings together such families of science as Stimulation and Genetically modified organism.
Tibor Keler mainly investigates Cancer research, Immunology, CD8, CD40 and Immune system. His Cancer research research is multidisciplinary, relying on both Agonist, Blockade, Priming and Cancer immunotherapy. His research in Blockade focuses on subjects like Antibody, which are connected to Proinflammatory cytokine.
His Immunology study frequently intersects with other fields, such as Ligand. As part of the same scientific family, he usually focuses on CD40, concentrating on T cell and intersecting with Myeloid. Tibor Keler studies Immune system, focusing on Immunotherapy in particular.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey;Florian Klein;Julio C. C. Lorenzi;Michael S. Seaman.
Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma
Kristin Sanderson;Ronald Scotland;Peter Lee;Dongxin Liu.
Journal of Clinical Oncology (2005)
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid;Johannes F. Scheid;Joshua A. Horwitz;Yotam Bar-On;Edward F. Kreider.
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Marina Caskey;Till Schoofs;Henning Gruell;Allison Settler.
Nature Medicine (2017)
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
James Schuster;Rose K. Lai;Rose K. Lai;Lawrence D. Recht;David A. Reardon;David A. Reardon.
Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
Madhav V. Dhodapkar;Mario Sznol;Biwei Zhao;Ding Wang.
Science Translational Medicine (2014)
Human monoclonal antibodies to her2/neu
Tibor Keler;Yashwant Deo.
Mannose receptor-targeted vaccines
Tibor Keler;Venky Ramakrishna;Michael W Fanger.
Expert Opinion on Biological Therapy (2004)
Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells.
Bithi Chatterjee;Bithi Chatterjee;Anna Smed-Sörensen;Anna Smed-Sörensen;Lillian Cohn;Cécile Chalouni.
Circulating precursors of human CD1c+ and CD141+ dendritic cells
Gaëlle Breton;Jaeyop Lee;Yu Jerry Zhou;Joseph J. Schreiber.
Journal of Experimental Medicine (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: